APS vs. BCT, IPA, TH, SCYB, COM, NVH, IGX, ONC, COV, and PDP
Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include BriaCell Therapeutics (BCT), ImmunoPrecise Antibodies (IPA), Theratechnologies (TH), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), IntelGenx Technologies (IGX), Oncolytics Biotech (ONC), Covalon Technologies (COV), and Pediapharm (PDP). These companies are all part of the "biotechnology" industry.
Aptose Biosciences vs. Its Competitors
Aptose Biosciences (TSE:APS) and BriaCell Therapeutics (CVE:BCT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.
15.1% of Aptose Biosciences shares are held by institutional investors. 17.1% of Aptose Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
BriaCell Therapeutics has a consensus target price of C$15.00, indicating a potential upside of 41.51%. Given BriaCell Therapeutics' higher probable upside, analysts clearly believe BriaCell Therapeutics is more favorable than Aptose Biosciences.
BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Aptose Biosciences had 3 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 3 mentions for Aptose Biosciences and 0 mentions for BriaCell Therapeutics. Aptose Biosciences' average media sentiment score of 0.53 beat BriaCell Therapeutics' score of 0.00 indicating that Aptose Biosciences is being referred to more favorably in the media.
Aptose Biosciences' return on equity of 1,017.48% beat BriaCell Therapeutics' return on equity.
Summary
Aptose Biosciences beats BriaCell Therapeutics on 8 of the 11 factors compared between the two stocks.
Get Aptose Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for APS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding APS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptose Biosciences Competitors List
Related Companies and Tools
This page (TSE:APS) was last updated on 7/5/2025 by MarketBeat.com Staff
